AEON,AEON Biopharma, Inc. | Healthcare

Healthcare

AEON

All stocks News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Commodities

AEON Biopharma, Inc.AEON

USD

- At close

USD

- Until the end

The complete list of US stocks

MAX

Overview >

% Change

Description >

AEON Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on developing botulinum toxins.

It develops ABP-450 (prabotulinumtoxinA) injection for debilitating medical conditions, which completed a Phase 2 study for the treatment of cervical dystonia and has an ongoing Phase 2 study for the treatment of both chronic and episodic migraine.

AEON Biopharma, Inc. is based in Irvine, California.

Latest News >

ARM Holdings Fiscal Q3 Non-GAAP Earnings, Revenue Rise; Q4, FY Guidance Set; Shares Fall After Hours

Feb 5, 2025

04:39 PM EST, 02/05/2025 (MT Newswires) -- ARM Holdings ( ARM ) reported fiscal Q3 non-GAAP earnings late Wednesday of $0.39 per diluted share, up from $0.31 a year earlier. Analysts polled by FactSet expected $0.34. Revenue in the three months ended Dec. 31 rose to $983 million from $824 million a year earlier. Analysts surveyed by FactSet expected $949.3...

Align Technology Q4 Non-GAAP Earnings, Revenue Rise

Feb 5, 2025

04:40 PM EST, 02/05/2025 (MT Newswires) -- Align Technology ( ALGN ) reported Q4 non-GAAP earnings late Wednesday of $2.44 per diluted share, up from $2.42 a year earlier. Analysts polled by FactSet expected $2.45. Net revenue for the quarter ended Dec. 31 was $995.2 million, up from $956.7 million a year earlier. Analysts surveyed by FactSet expected $996.9 million....

Crown Holdings Q4 Adjusted Earnings, Net Sales Increase -- Shares Rise After Hours

Feb 5, 2025

04:40 PM EST, 02/05/2025 (MT Newswires) -- Crown Holdings ( CCK ) reported Q4 adjusted earnings late Wednesday of $1.59 per diluted share, up from $1.24 a year earlier. Analysts polled by FactSet expected $1.50. Net sales for the quarter ended Dec. 31 was $2.90 billion, up from $2.86 billion a year earlier. Analysts surveyed by FactSet expected $2.89 billion....

Strategy Q4 Earnings: Bitcoin Treasury Company Spends $20.5B On BTC, Shares Inch Higher Despite Revenue Miss

Feb 5, 2025

MicroStrategy Inc ( MSTR ) , which announced a rebrand to Strategy on Wednesday, reported fourth-quarter financial results after the market close. Here’s a look at the key details from the quarter. Q4 Earnings: Strategy reported fourth-quarter revenue of $120.7 million, missing analyst estimates of $123.25 million, according to Benzinga Pro. The Bitcoin (CRYPTO: BTC) treasury company reported a fourth-quarter...